NCT02359019View on ClinicalTrials.gov

MK-3475 as Maintenance Therapy in Extensive Stage SCLC

PHASE2CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

February 28, 2015

Primary Completion Date

October 31, 2018

Study Completion Date

October 31, 2018

Conditions
Extensive Stage Small Cell Lung Carcinoma
Interventions
BIOLOGICAL

Pembrolizumab

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

Trial Locations (5)

17033

Penn State Milton S. Hershey Medical Center, Hershey

44195

Cleveland Clinic, Cleveland

48109

University of Michigan, Ann Arbor

48201

Barbara Ann Karmanos Cancer Institute, Detroit

60612

Rush University Medical Center, Chicago

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Barbara Ann Karmanos Cancer Institute

OTHER

NCT02359019 - MK-3475 as Maintenance Therapy in Extensive Stage SCLC | Biotech Hunter | Biotech Hunter